Vanzacaftor

Vanzacaftor (VX-121) is an orally active noval corrector of Cystic fibrosis transmembrane conductance regulator (CFTR) . Vanzacaftor improves processing and trafficking of CFTR protein as well as increases chloride transport in triple combined with Tezacaftor (HY-15448) and Deutivacaftor. Vanzacaftor-Tezacaftor-Deutivacaftor is safe and well tolerated, improving lung function, respiratory symptoms, and CFTR function with cystic fibrosis, which is promising for research in the field of cystic fibrosis diseases[1][2].

Product Specifications

CAS Number

[2374124-49-7]

Product Name Alternative

VX-121

UNSPSC

12352005

Target

CFTR; Chloride Channel

Type

Reference compound

Related Pathways

Membrane Transporter/Ion Channel

Applications

COVID-19-immunoregulation

Field of Research

Neurological Disease

Assay Protocol

https://www.medchemexpress.com/vanzacaftor.html

Purity

98.72

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

CC(C)(C[C@@](CCC/N=C1NC(S(=O)(N2)=O)=CC=C\1)([H])C3)N3C4=NC(N(C=C5)N=C5OCCC6C7(CC7)C68CC8)=CC=C4C2=O

Molecular Formula

C32H39N7O4S

Molecular Weight

617.76

References & Citations

[1]Uluer AZ, et al. Safety and efficacy of vanzacaftor-tezacaftor-deutivacaftor in adults with cystic fibrosis: randomised, double-blind, controlled, phase 2 trials[J]. Lancet Respir Med. 2023 Jun;11 (6) :550-562.|[2]Kolski-Andreaco A, et al. Potentiation of BKCa channels by cystic fibrosis transmembrane conductance regulator (CFTR) correctors VX-445 and VX-121[J]. J Clin Invest. 2024 Jul 2:e176328.